Clinical Trial FailuresThe ReThink-ALZ Phase 3 trial with simufilam did not meet its primary and secondary endpoints in Alzheimer’s patients.
Regulatory And Financial RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.
Stock PerformanceThe stock is expected to remain range-bound due to uncertainties in simufilam's clinical advancement.